Bani-Hani Ahmad H, Leibovich Bradley C, Lohse Christine M, Cheville John C, Zincke Horst, Blute Michael L
Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA.
J Urol. 2005 Feb;173(2):391-4. doi: 10.1097/01.ju.0000148951.71353.8b.
We determined the incidence of and factors associated with the development of renal cell carcinoma (RCC) in the contralateral kidney after nephrectomy for localized RCC.
Between 1970 and 2000, 2,352 patients with sporadic, localized unilateral RCC and a normal contralateral kidney underwent nephrectomy for RCC. Cancer specific survival rates were estimated using the Kaplan-Meier method. Univariate Cox proportional hazards models were used to determine associations with outcome.
Of the 2,352 patients studied 28 (1.2%) had RCC in the contralateral kidney, including 20 with clear cell and 8 with papillary RCC. Mean time from primary surgery to contralateral recurrence was 5.2 years (median 4.8, range 0 to 18) for clear cell RCC compared with 5.6 years (median 1.3, range 0 to 21) for papillary cell RCC. Positive surgical margins (risk ratio 14.23, p = 0.010) and multifocality (risk ratio 5.74, p = 0.019) were significantly associated with contralateral recurrence following nephrectomy for clear cell RCC, while nuclear grade (risk ratio for grades 3/4 vs 1/2, 4.78, p = 0.040) was significantly associated with contralateral recurrence following nephrectomy for papillary RCC. In patients with clear cell RCC estimated cancer specific survival rates 1, 3, and 5 years following contralateral recurrence were 93.8%, 80.2% and 72.9%, respectively.
In patients with localized RCC and a normal contralateral kidney who underwent nephrectomy for RCC positive surgical margins and multifocality were significant predictors of contralateral recurrence for clear cell RCC, while nuclear grade was a significant predictor of contralateral recurrence for papillary RCC.
我们确定了局限性肾细胞癌(RCC)肾切除术后对侧肾脏发生肾细胞癌(RCC)的发生率及相关因素。
1970年至2000年间,2352例散发性、局限性单侧RCC且对侧肾脏正常的患者接受了RCC肾切除术。采用Kaplan-Meier法估计癌症特异性生存率。单因素Cox比例风险模型用于确定与预后的关联。
在研究的2352例患者中,28例(1.2%)对侧肾脏发生RCC,其中20例为透明细胞癌,8例为乳头状RCC。透明细胞RCC从初次手术到对侧复发的平均时间为5.2年(中位数4.8年,范围0至18年),而乳头状细胞RCC为5.6年(中位数1.3年,范围0至21年)。透明细胞RCC肾切除术后,手术切缘阳性(风险比14.23,p = 0.010)和多灶性(风险比5.74,p = 0.019)与对侧复发显著相关,而乳头状RCC肾切除术后,核分级(3/4级与1/2级的风险比,4.78,p = 0.040)与对侧复发显著相关。透明细胞RCC患者对侧复发后1年、3年和5年的估计癌症特异性生存率分别为93.8%、80.2%和72.9%。
对于局限性RCC且对侧肾脏正常并接受RCC肾切除术的患者,手术切缘阳性和多灶性是透明细胞RCC对侧复发的重要预测因素,而核分级是乳头状RCC对侧复发的重要预测因素。